Baxter's (BAX) Latest FDA Approval to Boost Infusion Therapy

Published on 2 Apr 2024 on Zacks via Yahoo Finance

Baxter's (BAX) Latest FDA Approval to Boost Infusion Therapy

Baxter International Inc. BAX recently received the FDA’s 510(k) clearance for its Novum IQ large volume infusion pump (LVP) with Dose IQ Safety Software. Adding LVP modality to the Novum IQ Infusion Platform, which includes Baxter’s syringe infusion pump (SYR) with Dose IQ Safety Software, powered by the IQ Enterprise Connectivity Suite, is expected to enable clinicians to utilize a single, integrated system across a variety of patient care settings.

Baxter expects to expand the platform in the future via continued product development and additional regulatory submissions.

The Novum IQ LVP and Novum IQ SYR are currently available to order in the United States.

Read the rest of the article

NYSE.BAX price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

News

Baxter's (BAX) Latest FDA Approval to Boost Infusion Therapy

NYSE.BAX price evolution

Want to become a better investor?

Baxter's (BAX) New Injectables Aid Its Pharmaceutical Portfolio

Baxter introduces new injectable pharmaceuticals to US market

Reasons to Hold Baxter International (BAX) in Your Portfolio

Baxter Is Deeply Undervalued

Shareholders in Baxter International (NYSE:BAX) are in the red if they invested three years ago

S&P 500 Falls 1% as Oil Jump Spurs Flight to Bonds: Markets Wrap

Baxter's (BAX) Latest FDA Approval to Boost Infusion Therapy

Novo kidney trial finds Ozempic cuts cardiac deaths in diabetics

Insider Sell: EVP, Chief HR Officer Jeanne Mason Sells 64,488 Shares of Baxter International ...

Dialysis providers gain as investors focus on cardiac benefits after Ozempic's latest data